Every week, a group of epidemiologists across the north-east of the United States joins a Zoom call entirely devoted to discussing the latest hints of new Covid-19 variants being reported around the world.
"It's like the weather report," says William Hanage, an epidemiologist at the Harvard TH Chan School of Public Health. "It used to be, 'We have a little bit of Gamma there, we've got Alpha coming up here.' But now it's just Delta."
Since it was first detected in India in December 2020, the Delta variant of Sars-CoV-2 has become so ubiquitous that it would be easy to assume that the once-rapid evolution of the virus has been replaced by a state of quiescence. According to the World Health Organization, 99.5% of all Covid-19 genomic sequences reported to public databases are now Delta.
While new strains have continued to emerge, such as the recent AY. 4.2 or the Delta Plus variant in the UK, which scientists estimate to be 10-15% more transmissible, although there is no exact data for this yet, they are almost identical to the Delta variant, apart from the odd minor mutation here and there. Hanage has taken to referring to them as Delta's grandchildren.
"There's been quite a few Delta Pluses," he says. "I did a recent radio interview where I said that Delta Plus is code for whatever people are getting their knickers in a twist about at the moment. It's not gigantically more transmissible."
But the reason Hanage and colleagues still scan databases such as Pangolin and Nextstrain each week, and the purpose of their regular Zoom calls, is to try and predict what might come next. Is Delta really Covid-19's endgame or is something more ominous looming in the future? It is a question to which no one is entirely sure of the answer.
It's inevitable there will be another significant variant in the next two years – and it may out-compete Delta
Prof Ravi Gupta, University of Cambridge
One possibility is that after the initial dramatic jumps in its genetic sequence, which gave rise to first Alpha, then Delta, Sars-CoV-2 will now mutate slowly and steadily, eventually moving beyond reach of the current vaccines, but only over the course of many years. While scientists are at pains to point out that their predictions are mostly informed speculation, some perceive this as the most likely outcome.
"I anticipate that the kind of evolution we will see is more what we call antigenic drift, where the virus gradually evolves to escape the immune system," says Francois Balloux, director of the UCL Genetics Institute. "For influenza and other coronaviruses we know quite well, it takes about 10 years for the virus to accumulate enough changes not to be recognised by antibodies in the blood."
But the alternative is the sudden appearance of a completely new strain, with game-changing transmissibility, virulence or immune-evasive properties. Ravi Gupta, professor of clinical microbiology at the University of Cambridge, refers to these strains as "super variants" and says he is 80% sure that another one will emerge. The question is when.
"We've got a Delta pandemic at the moment," says Gupta. "This new Delta Plus variant is relatively wimpy compared to the kind of thing I'm talking about. It has two mutations from the Delta strain, I don't think they are that worrisome and it hasn't taken off in a big way in other countries. But it's inevitable that there will be another significant variant in the next two years and it will compete with Delta and it may out-compete Delta."
There are a number of ways in which this might arise.
Will we see a super variant?
During the latter half of 2020, epidemiologists began to observe signs of a concerning phenomenon known as viral recombination, in which different versions of Sars-CoV-2 exchanged mutations and combined to form a totally new strain.
Thankfully, Gupta says recombination does not appear to be that common, but it remains one feasible source of a new super variant, particularly in parts of the world where sizable proportions of the population remain unvaccinated and viral strains can circulate freely. "Now that Delta is overwhelmingly the key virus, this has become less likely," he says. "But there are large swaths of the planet that we're not sampling and we don't know what's going on. So it is a very real possibility."
More complex mutations can evolve in the future, which may be more problematic…
News
Our books now available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
Younger Generations Are Aging Faster – and It May Be Fueling a Surge in Cancer
Younger generations may be aging biologically faster than those before them, and that shift could help explain rising rates of cancer at younger ages. For decades, cancer was viewed largely as a disease of [...]
Using Cannabis Could Raise Your Stroke Risk by 37%, Massive Study Reveals
Large-scale evidence suggests cannabis, cocaine, and amphetamines may directly raise stroke risk, including in younger adults. As recreational drug use becomes increasingly common, researchers are uncovering evidence that its health consequences may extend far beyond [...]
Could Vitamin C Be the Secret to Keeping Your Brain Younger?
Lower vitamin C levels were linked to reduced brain volume and weaker neural connectivity in older adults, suggesting a potential connection between nutrition and brain health. Could a common vitamin help preserve the brain [...]
This Deadly Disease Was Wiping Out Humans 5,500 Years Ago
A new study suggests plague was already a deadly threat 5,500 years ago, striking small hunter-gatherer communities long before cities and agriculture emerged. For centuries, plague has been remembered as the disease that devastated [...]
China closing in but US leads in biotech quality, commercial reach, survey finds
SAN DIEGO, June 22 (Reuters) - China, which now conducts more clinical drug trials, opens new tab than the U.S., still lags in the quality and commercial reach of its biomedical science, according to a recent survey, opens new [...]
New method generates renewable supply of progenitor immune cells
In a paper published in Cell, a USC Stem Cell-led team reports a new way of generating a renewable and expandable supply of the progenitor cells that give rise to macrophages. These immune cells help [...]
Scientists Just Discovered a Cellular Survival System That Was Never Supposed To Exist
A surprising backup pathway allows cells to make a crucial amino acid when their primary machinery fails. For decades, biologists believed cells had only one way to access a molecule they cannot live without. New [...]
Artificial cells gain porous membranes, enabling lab reactions and drug release
Artificial cells created in the laboratory offer a wide range of potential applications. Until now, however, their membranes—unlike those of real cells—have been virtually impermeable. Researchers at the Max Planck Institute for Polymer Research, [...]
Popular Weight-Loss Drugs Like Ozempic Linked to Lower Breast Cancer Risk
Ozempic and similar weight-loss drugs were linked to a striking 30% reduction in breast cancer risk in a study of more than 110,000 women. Popular weight-loss and diabetes medications such as Ozempic, Wegovy, Mounjaro, [...]
Stanford Scientists Discover Explosive New Type of Immune Cell
Scientists studying the remarkable regenerative abilities of planarian flatworms have uncovered a previously unknown type of immune cell with an unusually destructive defense strategy. What if an immune cell could wipe out nearby threats [...]
Big Pharma-backed SonoThera sounds off with $125M series B for bubble-based genetic delivery
Bay Area biotech SonoThera is bubbling to a clinical boil after raising a $125 million series B with the backing of some of the biggest names in pharma. Vida Ventures led the raise, with the venture [...]
Joint initiative of 5 EU countries calls for ‘unified approach’ to pharma framework amid US drug pricing pressure
With drug pricing pressure building from the U.S., a healthcare-focused consortium of five European countries is calling for a “unified approach” to strengthen Europe’s pharmaceutical framework and access to innovative medicines. Belgium, the Netherlands, [...]
Molecular Manufacturing: The Future of Nanomedicine – New book from NanoappsMedical Inc.
This book explores the revolutionary potential of atomically precise manufacturing technologies to transform global healthcare, as well as practically every other sector across society. This forward-thinking volume examines how envisaged Factory@Home systems might enable the cost-effective [...]
NanoMedical Brain/Cloud Interface – Explorations and Implications. A new book from Frank Boehm
New book from Frank Boehm, NanoappsMedical Inc Founder: This book explores the future hypothetical possibility that the cerebral cortex of the human brain might be seamlessly, safely, and securely connected with the Cloud via [...]
New book from Nanoappsmedical Inc. – Global Health Care Equivalency
A new book by Frank Boehm, NanoappsMedical Inc. Founder. This groundbreaking volume explores the vision of a Global Health Care Equivalency (GHCE) system powered by artificial intelligence and quantum computing technologies, operating on secure [...]















